Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

Stopped Per FDA CBER letter dated July 15, 2015, Kedrion SpA was released from the PMC to perform the study with Kedbumin 25% in pediatric patients.

Conditions

• Hypovolemia

Interventions

• DRUG: Kedbumin 25%
• DRUG: Normal Saline Solution

Sponsor

Kedrion S.p.A.

Collaborators

• [object Object]